Kow-Tong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kow-Tong Chen has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
Kou-Huang Chen
School of Mechanical and Electronic Engineering, Sanming University, Sanming, Fujian, China
10 shared publicationsHsiao-Ling Chang
Division of Infection Control and Biosafety, Centers for Disease Control, Ministry of Health and Welfare, Taipei, Taiwan
8 shared publicationsShih-Bin Su
Department of Occupational Medicine, Chi Mei Medical Center, Tainan 710, Taiwan
8 shared publicationsKwo-Liang Chen
Department of Industrial Engineering and Management, China University of Science and Technology, Taipei, Taiwan
5 shared publications- Ping-Chin Chang
Division of Infectious Diseases, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Tainan 736, Taiwan
5 shared publications Shiing-Jer Twu
Department of Health, Executive Yuan, Taiwan
5 shared publications
Latest Publications
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF9
Association of Low Serum Vitamin B12 Concentration with Colorectal Cancer Risk and All-Cause Mortality: A Global Multi-institutional Retrospective Cohort Study
Background: The association between vitamin B12 deficiency and colorectal cancer risk remains uncertain. We evaluated the association between low serum vitamin B12 concentration (<200 pg/mL) and colorectal cancer incidence and all-cause mortality, using a midrange reference group (400–600 pg/mL). Methods: In this retrospective propensity score–matched cohort study, adults with serum B12 measurements between 2006 and 2020 were identified from the TriNetX Global Collaborative Network. Patients with any neoplasm diagnosis within 5 years before the index date (first B12 measurement) were excluded. Patients with B12 < 200 pg/mL were matched 1:1 to those with 400 to 600 pg/mL and followed for up to 10 years. Time-stratified, landmark, subgroup, E value, and outcome–control analyses were performed. Results: After matching, 184,126 pairs were included. Low serum B12 was associated with a higher colorectal cancer risk (hazard ratio (HR), 1.16; 95% confidence interval (CI), 1.09–1.23) and all-cause mortality (HR, 1.16; 95% CI, 1.14–1.18). The colorectal cancer association persisted at the 2-year landmark (HR, 1.16; 95% CI, 1.07–1.26) but attenuated at the 3-year (HR, 1.07; 95% CI, 0.98–1.18) and 5-year (HR, 1.12; 95% CI, 0.99–1.25) landmarks, whereas all-cause mortality remained elevated across all landmarks. The appendicitis negative control was null (HR, 0.92; 95% CI, 0.84–1.02), whereas the clavicle fracture was weakly positive (HR, 1.08; 95% CI, 1.01–1.16). Conclusions: Low serum vitamin B12 was associated with higher all-cause mortality; its association with colorectal cancer was less robust at longer landmarks. Impact: The mortality association was more robust; the colorectal cancer finding requires prospective confirmation with serial B12 measurements.
- 30 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF9
Association of Low Serum Vitamin B12 Concentration with Colorectal Cancer Risk and All-Cause Mortality: A Global Multi-institutional Retrospective Cohort Study
Background: The association between vitamin B12 deficiency and colorectal cancer risk remains uncertain. We evaluated the association between low serum vitamin B12 concentration (<200 pg/mL) and colorectal cancer incidence and all-cause mortality, using a midrange reference group (400–600 pg/mL). Methods: In this retrospective propensity score–matched cohort study, adults with serum B12 measurements between 2006 and 2020 were identified from the TriNetX Global Collaborative Network. Patients with any neoplasm diagnosis within 5 years before the index date (first B12 measurement) were excluded. Patients with B12 < 200 pg/mL were matched 1:1 to those with 400 to 600 pg/mL and followed for up to 10 years. Time-stratified, landmark, subgroup, E value, and outcome–control analyses were performed. Results: After matching, 184,126 pairs were included. Low serum B12 was associated with a higher colorectal cancer risk (hazard ratio (HR), 1.16; 95% confidence interval (CI), 1.09–1.23) and all-cause mortality (HR, 1.16; 95% CI, 1.14–1.18). The colorectal cancer association persisted at the 2-year landmark (HR, 1.16; 95% CI, 1.07–1.26) but attenuated at the 3-year (HR, 1.07; 95% CI, 0.98–1.18) and 5-year (HR, 1.12; 95% CI, 0.99–1.25) landmarks, whereas all-cause mortality remained elevated across all landmarks. The appendicitis negative control was null (HR, 0.92; 95% CI, 0.84–1.02), whereas the clavicle fracture was weakly positive (HR, 1.08; 95% CI, 1.01–1.16). Conclusions: Low serum vitamin B12 was associated with higher all-cause mortality; its association with colorectal cancer was less robust at longer landmarks. Impact: The mortality association was more robust; the colorectal cancer finding requires prospective confirmation with serial B12 measurements.
- Open Access
- 8 September 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (9) , 252
Severe Dengue in Children: Pathogenesis, Early Recognition, and Evidence-Informed Management
Severe dengue remains an important cause of pediatric hospitalization, morbidity, and mortality in tropical and subtropical regions, particularly where rapid triage and pediatric critical-care capacity are limited. This structured narrative review synthesizes the evidence on the epidemiology, pathogenesis, early recognition, diagnosis, management, and prevention of severe dengue in children. Severe disease reflects interactions among viral factors, pre-existing immunity, dysregulated host responses, and microvascular endothelial injury. Antibody-dependent enhancement, inflammatory mediators, dengue nonstructural protein 1, and endothelial glycocalyx disruption contribute to vascular hyperpermeability, plasma leakage, shock, severe bleeding, and organ impairment. Because deterioration often occurs abruptly around defervescence, serial clinical assessment, hematocrit trends, urine-output monitoring, and timely recognition of warning signs are central to risk stratification. Molecular assays and NS1 antigen testing are most useful during the early febrile phase, although diagnostic performance varies with illness timing and immune status. Carefully titrated isotonic crystalloid therapy remains the cornerstone of treatment; both delayed resuscitation and excessive fluid administration may worsen outcomes. Reducing mortality requires integrated clinical and public-health strategies combining standardized pediatric management, accessible diagnostics, effective referral systems, vaccination where appropriate, surveillance, and vector control.
- 8 September 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (9) , 252
Open AccessSevere Dengue in Children: Pathogenesis, Early Recognition, and Evidence-Informed Management
Severe dengue remains an important cause of pediatric hospitalization, morbidity, and mortality in tropical and subtropical regions, particularly where rapid triage and pediatric critical-care capacity are limited. This structured narrative review synthesizes the evidence on the epidemiology, pathogenesis, early recognition, diagnosis, management, and prevention of severe dengue in children. Severe disease reflects interactions among viral factors, pre-existing immunity, dysregulated host responses, and microvascular endothelial injury. Antibody-dependent enhancement, inflammatory mediators, dengue nonstructural protein 1, and endothelial glycocalyx disruption contribute to vascular hyperpermeability, plasma leakage, shock, severe bleeding, and organ impairment. Because deterioration often occurs abruptly around defervescence, serial clinical assessment, hematocrit trends, urine-output monitoring, and timely recognition of warning signs are central to risk stratification. Molecular assays and NS1 antigen testing are most useful during the early febrile phase, although diagnostic performance varies with illness timing and immune status. Carefully titrated isotonic crystalloid therapy remains the cornerstone of treatment; both delayed resuscitation and excessive fluid administration may worsen outcomes. Reducing mortality requires integrated clinical and public-health strategies combining standardized pediatric management, accessible diagnostics, effective referral systems, vaccination where appropriate, surveillance, and vector control.
- Open Access
- 22 September 2025
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 156 (1)
A review of occupational noise-induced hearing loss: focus on mechanisms and preventive measures
Introduction: This research investigates the epidemiology, underlying mechanisms, and prevention strategies associated with occupational noise-induced hearing loss (ONIHL), while also presenting effective control measures. Source of data: Relevant literature was sourced from databases such as MEDLINE, PubMed, Embase, Web of Science, and Google Scholar, encompassing articles until February 2025. Areas of agreement: ONIHL is widely recognized as a common occupational health issue among workers. Additionally, noise can lead to psychological and physiological complications beyond direct auditory damage. Areas of controversy: The effects of noise differ across individuals, and the precise causes behind ONIHL remain poorly understood, although several pathways have been proposed. Growing points: New treatment options focused on oxidative stress, inflammation, and neuropathy are being developed through innovative drug delivery systems. Areas timely for developing research: There is a pressing need for molecular approaches to explore the mechanisms of ONIHL, particularly in the care of individuals with hearing disabilities.
- 22 September 2025
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 156 (1)
Open AccessA review of occupational noise-induced hearing loss: focus on mechanisms and preventive measures
Introduction: This research investigates the epidemiology, underlying mechanisms, and prevention strategies associated with occupational noise-induced hearing loss (ONIHL), while also presenting effective control measures. Source of data: Relevant literature was sourced from databases such as MEDLINE, PubMed, Embase, Web of Science, and Google Scholar, encompassing articles until February 2025. Areas of agreement: ONIHL is widely recognized as a common occupational health issue among workers. Additionally, noise can lead to psychological and physiological complications beyond direct auditory damage. Areas of controversy: The effects of noise differ across individuals, and the precise causes behind ONIHL remain poorly understood, although several pathways have been proposed. Growing points: New treatment options focused on oxidative stress, inflammation, and neuropathy are being developed through innovative drug delivery systems. Areas timely for developing research: There is a pressing need for molecular approaches to explore the mechanisms of ONIHL, particularly in the care of individuals with hearing disabilities.
- Open Access
- 28 February 2025
- Published by National Center for Global Health and Medicine (JST) in Global Health & Medicine
- Vol. 7 (1) , 1-12
A Review of epidemiology, diagnosis, and management of Mpox: The role of One Health
Human monkeypox (Mpox) is an emerging zoonotic disease. Its clinical features are similar to but less severe than those of smallpox. The etiology of this disease is the monkeypox virus. This virus is a double-stranded DNA virus that is classified into the genus Orthopoxvirus and the family Poxviridae. Human monkeypox was first identified in 1970 and mainly occurred in Central and Western Africa. In 2022, outbreaks of Mpox virus infection occurred in several non-endemic countries and caused a potential threat to humans. It is urgent to take immediate action to control and prevent the outbreak of the Mpox virus infection. This paper summarizes the current status of Mpox and generated strategies for managing the Mpox epidemic. Although progress in the diagnostic methods and treatment of Mpox produces better knowledge, we argue that the sensitive surveillance for animal and human Mpox virus infection and evidence-based response and management of Mpox outbreaks is critical. This study highlights the need for further research on preventive and control strategies for Mpox disease approached through the One Health concept.
- 28 February 2025
- Published by National Center for Global Health and Medicine (JST) in Global Health & Medicine
- Vol. 7 (1) , 1-12
Open AccessA Review of epidemiology, diagnosis, and management of Mpox: The role of One Health
Human monkeypox (Mpox) is an emerging zoonotic disease. Its clinical features are similar to but less severe than those of smallpox. The etiology of this disease is the monkeypox virus. This virus is a double-stranded DNA virus that is classified into the genus Orthopoxvirus and the family Poxviridae. Human monkeypox was first identified in 1970 and mainly occurred in Central and Western Africa. In 2022, outbreaks of Mpox virus infection occurred in several non-endemic countries and caused a potential threat to humans. It is urgent to take immediate action to control and prevent the outbreak of the Mpox virus infection. This paper summarizes the current status of Mpox and generated strategies for managing the Mpox epidemic. Although progress in the diagnostic methods and treatment of Mpox produces better knowledge, we argue that the sensitive surveillance for animal and human Mpox virus infection and evidence-based response and management of Mpox outbreaks is critical. This study highlights the need for further research on preventive and control strategies for Mpox disease approached through the One Health concept.
- Open Access
- 13 December 2024
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (1) , e4641
Nutritional, Nutraceutical, and Medicinal Potential of Cantharellus cibarius Fr.: A Comprehensive Review
Mushrooms are considered as nutraceutical foods that can effectively prevent diseases such as cancer and other serious life‐threatening conditions include neurodegeneration, hypertension, diabetes, and hypercholesterolemia. The Cantharellus cibarius, also known as the “Golden chanterelle” or “Golden girolle,” is a significant wild edible ectomycorrhizal mushroom. It is renowned for its delicious, apricot‐like aroma and is highly valued in various culinary traditions worldwide. It is well known for its nutritional, nutraceutical, and therapeutic properties. The high nutritional value of C. cibarius is attributed to its abundant carbohydrates, proteins, β‐glucans, dietary fiber, and low‐fat content. It also contains medicinal polysaccharides (β‐glucans), proteins (lectins and selenoproteins), important fatty acids (linoleic and omega‐6), vitamins, and minerals (N, P, K, Ca, Zn, Ag, Se, etc.). The sporocarp of C. cibarius contains a diverse array of bioactive metabolites, including flavonoids, phenolics, sterols, fatty acids, organic acids, indole groups, carbohydrates, vitamins (tocopherols), amino acids, enzymes, bioelements, carotenoids, and 5ˊ‐nucleotides. C. cibarius has a wide array of biological properties, such as antioxidant, anticancer, anti‐inflammatory, antifungal, antibacterial, anthelmintic, insecticidal, antihypoxia, antihyperglycemic, wound‐healing, cytotoxic, and iron‐chelating activity. Thus, the present review gives an overview of C. cibarius, covering its chemical composition, ecological significance, postharvest preservation strategies, and potential applications in dietary supplements, nutraceuticals, and pharmaceuticals. It also dives into the etymology, taxonomy, and global distribution of the renowned “Golden Chanterelle.” Furthermore, there is a need to valorize waste materials created during production and processing, as well as to acquire a thorough understanding of the mechanisms of action of bioactive compounds in mushrooms.
- 13 December 2024
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (1) , e4641
Open AccessNutritional, Nutraceutical, and Medicinal Potential of Cantharellus cibarius Fr.: A Comprehensive Review
Mushrooms are considered as nutraceutical foods that can effectively prevent diseases such as cancer and other serious life‐threatening conditions include neurodegeneration, hypertension, diabetes, and hypercholesterolemia. The Cantharellus cibarius, also known as the “Golden chanterelle” or “Golden girolle,” is a significant wild edible ectomycorrhizal mushroom. It is renowned for its delicious, apricot‐like aroma and is highly valued in various culinary traditions worldwide. It is well known for its nutritional, nutraceutical, and therapeutic properties. The high nutritional value of C. cibarius is attributed to its abundant carbohydrates, proteins, β‐glucans, dietary fiber, and low‐fat content. It also contains medicinal polysaccharides (β‐glucans), proteins (lectins and selenoproteins), important fatty acids (linoleic and omega‐6), vitamins, and minerals (N, P, K, Ca, Zn, Ag, Se, etc.). The sporocarp of C. cibarius contains a diverse array of bioactive metabolites, including flavonoids, phenolics, sterols, fatty acids, organic acids, indole groups, carbohydrates, vitamins (tocopherols), amino acids, enzymes, bioelements, carotenoids, and 5ˊ‐nucleotides. C. cibarius has a wide array of biological properties, such as antioxidant, anticancer, anti‐inflammatory, antifungal, antibacterial, anthelmintic, insecticidal, antihypoxia, antihyperglycemic, wound‐healing, cytotoxic, and iron‐chelating activity. Thus, the present review gives an overview of C. cibarius, covering its chemical composition, ecological significance, postharvest preservation strategies, and potential applications in dietary supplements, nutraceuticals, and pharmaceuticals. It also dives into the etymology, taxonomy, and global distribution of the renowned “Golden Chanterelle.” Furthermore, there is a need to valorize waste materials created during production and processing, as well as to acquire a thorough understanding of the mechanisms of action of bioactive compounds in mushrooms.
- Open Access
- 2 December 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1502819
Metabolomics and network pharmacology–guided analysis of TNF-α expression by Argemone mexicana (Linn) targeting NF-kB the signalling pathway in cancer cell lines
Introduction: Cancer has emerged as one of the leading causes of fatality all over the world. Phytoconstituents are being studied for their synergistic effects, which include disease prevention by altering molecular pathways and immunomodulation without side effects. The present experiment aims to explore the cancer preventive activities of Argemone mexicana Linn leaves extract in skin cancer cell lines (A431) and colon cancer cell lines (COLO 320DM)). In addition, TNF-α expression patterns and NF-kB signaling pathways have been examined.Methods: LC/MS study of Argemone mexicana Linn extracts in various solvents revealed anti-cancerous phytoconstituents. Network pharmacology analysis used Binding DB, STRING, DAVID, and KEGG for data mining to evaluate predicted compounds using functional annotation analysis. Cytoscape 3.2.1 created “neighbourhood approach” and networks. The MNTD of these extracts was tested on L929 fibroblasts. Skin cancer (A431) and colon cancer (COLO 320DM) cell lines were tested for IC50 inhibition. Evaluation of TNF-α and NF-kB expression in cell culture supernatants and homogenates reveals anti-cancerous effects.Results: LC-MS analysis of extracts predicted the presence of anticancer alkaloids Berberine, Atropine, Argemexicin, and Argemonin. In Network pharmacology analysis, enrichment was linked to the PI3-AKT pathway for both cancer types. MNTD was calculated at 1000μg/ml in L929. The ethanolic extract at 1000μg/ml significantly inhibited skin cancer cell proliferation by 67% and colon cancer cells by 75%. Ethanolic extract significantly reduced TNF-α expression in both cell lines (pArgemone mexicana Linn. known as ‘swarnkshiri’ in Ayurveda has been reported to be used by the traditional healers for the treatment of psoriasis and its anti-inflammatory and anti-cancerous properties, according to the Indian Medicinal Plant dictionary. In the experiment, the abatement in the expression of inflammatory cytokine TNF-α and inhibition of NF-kB transcription factor activation could be linked with the downregulation of cancer cell proliferation. The study revealed the anticancer activity of Argemone mexicana Linn in the cancer cell lines and paved a pathway for molecular approaches that could be explored more in In vivo studies.
- 2 December 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1502819
Open AccessMetabolomics and network pharmacology–guided analysis of TNF-α expression by Argemone mexicana (Linn) targeting NF-kB the signalling pathway in cancer cell lines
Introduction: Cancer has emerged as one of the leading causes of fatality all over the world. Phytoconstituents are being studied for their synergistic effects, which include disease prevention by altering molecular pathways and immunomodulation without side effects. The present experiment aims to explore the cancer preventive activities of Argemone mexicana Linn leaves extract in skin cancer cell lines (A431) and colon cancer cell lines (COLO 320DM)). In addition, TNF-α expression patterns and NF-kB signaling pathways have been examined.Methods: LC/MS study of Argemone mexicana Linn extracts in various solvents revealed anti-cancerous phytoconstituents. Network pharmacology analysis used Binding DB, STRING, DAVID, and KEGG for data mining to evaluate predicted compounds using functional annotation analysis. Cytoscape 3.2.1 created “neighbourhood approach” and networks. The MNTD of these extracts was tested on L929 fibroblasts. Skin cancer (A431) and colon cancer (COLO 320DM) cell lines were tested for IC50 inhibition. Evaluation of TNF-α and NF-kB expression in cell culture supernatants and homogenates reveals anti-cancerous effects.Results: LC-MS analysis of extracts predicted the presence of anticancer alkaloids Berberine, Atropine, Argemexicin, and Argemonin. In Network pharmacology analysis, enrichment was linked to the PI3-AKT pathway for both cancer types. MNTD was calculated at 1000μg/ml in L929. The ethanolic extract at 1000μg/ml significantly inhibited skin cancer cell proliferation by 67% and colon cancer cells by 75%. Ethanolic extract significantly reduced TNF-α expression in both cell lines (pArgemone mexicana Linn. known as ‘swarnkshiri’ in Ayurveda has been reported to be used by the traditional healers for the treatment of psoriasis and its anti-inflammatory and anti-cancerous properties, according to the Indian Medicinal Plant dictionary. In the experiment, the abatement in the expression of inflammatory cytokine TNF-α and inhibition of NF-kB transcription factor activation could be linked with the downregulation of cancer cell proliferation. The study revealed the anticancer activity of Argemone mexicana Linn in the cancer cell lines and paved a pathway for molecular approaches that could be explored more in In vivo studies.
- Open Access
- 4 September 2024
- Published by Taylor & Francis in Pathogens and Global Health
- Vol. 118 (7-8) , 538-548
A review of enterovirus-associated hand-foot and mouth disease: preventive strategies and the need for a global enterovirus surveillance network
Enterovirus (EV)-associated hand, foot, and mouth disease (HFMD) is a significant public health issue worldwide, commonly occurring in children five years of age or younger. The leading causes of most HFMD cases are EVs, which are members of the Picornaviridae family. The typical clinical manifestations of EV-associated HFMD are febrile presentations with mucosal herpangina, oral ulcerations, and skin rashes on the hands and feet. The majority of HFMD cases resolve without consequence; however, a subset progresses to severe neurological and cardiopulmonary complications, which can be fatal. In the past two decades, EV-associated HFMD has received significant attention. In this review, we organize published papers and provide updates on epidemiology, pathogenesis, surveillance, and vaccine developments for EV-associated HFMD. The impact of EV-associated HFMD is increasing globally. Developing efficacious vaccines has become a priority for preventing EV infections without adequate treatment. Simultaneously, emerging EV infections (including EV-D68, EV-A71, Coxsackieviruses, and echoviruses) are increasing, highlighting the need to create a vigilant surveillance system for EV infections worldwide.
- 4 September 2024
- Published by Taylor & Francis in Pathogens and Global Health
- Vol. 118 (7-8) , 538-548
Open AccessA review of enterovirus-associated hand-foot and mouth disease: preventive strategies and the need for a global enterovirus surveillance network
Enterovirus (EV)-associated hand, foot, and mouth disease (HFMD) is a significant public health issue worldwide, commonly occurring in children five years of age or younger. The leading causes of most HFMD cases are EVs, which are members of the Picornaviridae family. The typical clinical manifestations of EV-associated HFMD are febrile presentations with mucosal herpangina, oral ulcerations, and skin rashes on the hands and feet. The majority of HFMD cases resolve without consequence; however, a subset progresses to severe neurological and cardiopulmonary complications, which can be fatal. In the past two decades, EV-associated HFMD has received significant attention. In this review, we organize published papers and provide updates on epidemiology, pathogenesis, surveillance, and vaccine developments for EV-associated HFMD. The impact of EV-associated HFMD is increasing globally. Developing efficacious vaccines has become a priority for preventing EV infections without adequate treatment. Simultaneously, emerging EV infections (including EV-D68, EV-A71, Coxsackieviruses, and echoviruses) are increasing, highlighting the need to create a vigilant surveillance system for EV infections worldwide.
- Open Access
- 23 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (34) , e39006
An update of the diagnosis, treatment, and prevention of leprosy: A narrative review
Leprosy is an infectious disease that remains a public health concern. It is caused by acid-fast Bacillus leprae, which primarily affects the skin and peripheral nerves, potentially leading to long-term disability and stigma. However, current and previous efforts have focused on developing better diagnostic and therapeutic interventions for leprosy, and its prevention needs to be addressed. In this review, we organize the currently published papers and provide updates on the global epidemiology, diagnosis, treatment, and prevention of leprosy. Several online databases, including MEDLINE (National Library of Medicine, Bethesda, MD), PubMed, EMBASE, Web of Science, and Google Scholar, were searched to collect relevant published papers. As a public health issue, the World Health Organization set the goal of leprosy elimination with a prevalence of <1 case per 10,000 people, which was achieved in 2000 and in most countries by 2010, mainly owing to the treatment of leprosy using drugs starting in 1980 and no-cost access for patients since 1995. Although diagnostic and therapeutic techniques have improved, the new occurrence of leprosy remains a critical global disease burden. With continuous technological improvements in diagnosing and treating leprosy, obtaining more relevant healthcare knowledge and preventing leprosy disability are crucial.
- 23 August 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (34) , e39006
Open AccessAn update of the diagnosis, treatment, and prevention of leprosy: A narrative review
Leprosy is an infectious disease that remains a public health concern. It is caused by acid-fast Bacillus leprae, which primarily affects the skin and peripheral nerves, potentially leading to long-term disability and stigma. However, current and previous efforts have focused on developing better diagnostic and therapeutic interventions for leprosy, and its prevention needs to be addressed. In this review, we organize the currently published papers and provide updates on the global epidemiology, diagnosis, treatment, and prevention of leprosy. Several online databases, including MEDLINE (National Library of Medicine, Bethesda, MD), PubMed, EMBASE, Web of Science, and Google Scholar, were searched to collect relevant published papers. As a public health issue, the World Health Organization set the goal of leprosy elimination with a prevalence of <1 case per 10,000 people, which was achieved in 2000 and in most countries by 2010, mainly owing to the treatment of leprosy using drugs starting in 1980 and no-cost access for patients since 1995. Although diagnostic and therapeutic techniques have improved, the new occurrence of leprosy remains a critical global disease burden. With continuous technological improvements in diagnosing and treating leprosy, obtaining more relevant healthcare knowledge and preventing leprosy disability are crucial.
- Open Access
- 24 May 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1134802
Elucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches
There has been progressive improvement in immunoinformatics approaches for epitope-based peptide design. Computational-based immune-informatics approaches were applied to identify the epitopes of SARS-CoV-2 to develop vaccines. The accessibility of the SARS-CoV-2 protein surface was analyzed, and hexa-peptide sequences (KTPKYK) were observed having a maximum score of 8.254, located between amino acids 97 and 102, whereas the FSVLAC at amino acids 112 to 117 showed the lowest score of 0.114. The surface flexibility of the target protein ranged from 0.864 to 1.099 having amino acid ranges of 159 to 165 and 118 to 124, respectively, harboring the FCYMHHM and YNGSPSG hepta-peptide sequences. The surface flexibility was predicted, and a 0.864 score was observed from amino acids 159 to 165 with the hepta-peptide (FCYMHHM) sequence. Moreover, the highest score of 1.099 was observed between amino acids 118 and 124 against YNGSPSG. B-cell epitopes and cytotoxic T-lymphocyte (CTL) epitopes were also identified against SARS-CoV-2. In molecular docking analyses, -0.54 to -26.21 kcal/mol global energy was observed against the selected CTL epitopes, exhibiting binding solid energies of -3.33 to -26.36 kcal/mol. Based on optimization, eight epitopes (SEDMLNPNY, GSVGFNIDY, LLEDEFTPF, DYDCVSFCY, GTDLEGNFY, QTFSVLACY, TVNVLAWLY, and TANPKTPKY) showed reliable findings. The study calculated the associated HLA alleles with MHC-I and MHC-II and found that MHC-I epitopes had higher population coverage (0.9019% and 0.5639%) than MHC-II epitopes, which ranged from 58.49% to 34.71% in Italy and China, respectively. The CTL epitopes were docked with antigenic sites and analyzed with MHC-I HLA protein. In addition, virtual screening was conducted using the ZINC database library, which contained 3,447 compounds. The 10 top-ranked scrutinized molecules (ZINC222731806, ZINC077293241, ZINC014880001, ZINC003830427, ZINC030731133, ZINC003932831, ZINC003816514, ZINC004245650, ZINC000057255, and ZINC011592639) exhibited the least binding energy (-8.8 to -7.5 kcal/mol). The molecular dynamics (MD) and immune simulation data suggest that these epitopes could be used to design an effective SARS-CoV-2 vaccine in the form of a peptide-based vaccine. Our identified CTL epitopes have the potential to inhibit SARS-CoV-2 replication.
- 24 May 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1134802
Open AccessElucidation of novel compounds and epitope-based peptide vaccine design against C30 endopeptidase regions of SARS-CoV-2 using immunoinformatics approaches
There has been progressive improvement in immunoinformatics approaches for epitope-based peptide design. Computational-based immune-informatics approaches were applied to identify the epitopes of SARS-CoV-2 to develop vaccines. The accessibility of the SARS-CoV-2 protein surface was analyzed, and hexa-peptide sequences (KTPKYK) were observed having a maximum score of 8.254, located between amino acids 97 and 102, whereas the FSVLAC at amino acids 112 to 117 showed the lowest score of 0.114. The surface flexibility of the target protein ranged from 0.864 to 1.099 having amino acid ranges of 159 to 165 and 118 to 124, respectively, harboring the FCYMHHM and YNGSPSG hepta-peptide sequences. The surface flexibility was predicted, and a 0.864 score was observed from amino acids 159 to 165 with the hepta-peptide (FCYMHHM) sequence. Moreover, the highest score of 1.099 was observed between amino acids 118 and 124 against YNGSPSG. B-cell epitopes and cytotoxic T-lymphocyte (CTL) epitopes were also identified against SARS-CoV-2. In molecular docking analyses, -0.54 to -26.21 kcal/mol global energy was observed against the selected CTL epitopes, exhibiting binding solid energies of -3.33 to -26.36 kcal/mol. Based on optimization, eight epitopes (SEDMLNPNY, GSVGFNIDY, LLEDEFTPF, DYDCVSFCY, GTDLEGNFY, QTFSVLACY, TVNVLAWLY, and TANPKTPKY) showed reliable findings. The study calculated the associated HLA alleles with MHC-I and MHC-II and found that MHC-I epitopes had higher population coverage (0.9019% and 0.5639%) than MHC-II epitopes, which ranged from 58.49% to 34.71% in Italy and China, respectively. The CTL epitopes were docked with antigenic sites and analyzed with MHC-I HLA protein. In addition, virtual screening was conducted using the ZINC database library, which contained 3,447 compounds. The 10 top-ranked scrutinized molecules (ZINC222731806, ZINC077293241, ZINC014880001, ZINC003830427, ZINC030731133, ZINC003932831, ZINC003816514, ZINC004245650, ZINC000057255, and ZINC011592639) exhibited the least binding energy (-8.8 to -7.5 kcal/mol). The molecular dynamics (MD) and immune simulation data suggest that these epitopes could be used to design an effective SARS-CoV-2 vaccine in the form of a peptide-based vaccine. Our identified CTL epitopes have the potential to inhibit SARS-CoV-2 replication.